Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider’s Perspective
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
https://link.springer.com/content/pdf/10.1007/s11912-022-01330-z.pdf
Reference48 articles.
1. Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene cileleucel in relapsed or refractory indolent non-Hodgkin lymphoma (XUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncology. 2022;1:91–103. https://doi.org/10.10106/S1470-2045(21)00591-X.
2. •• Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EMBT (JACIE). Haematologica. 2020;105:297–316. https://doi.org/10.3324/haematol.2019.229781. (This editorial highlights the practical recommendations for CAR-T cell therapy patients, including how to manage and treat CRS and ICANS.)
3. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-Care Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. Clin Oncol. 2022;27:3119–28. https://doi.org/10.1200/JCO.19.02104.
4. Locke Frederick L, Miklos David B, Jacobson Caron A, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54. https://doi.org/10.1056/NEJMoa2116133.
5. Neelapu SS, Locke FL, Lekakis LJ, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New Engl J Med. 2017;26:2531–44. https://doi.org/10.1056/NEJMoa1707447.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CAR T-cell therapy: A collaboration between authorized treatment centers and community oncologists;Seminars in Oncology;2024-06
2. Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications;Heliyon;2024-04
3. Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy;Current Fungal Infection Reports;2023-03-18
4. Rehabilitation of patients after CAR T-cell therapy. Experiences on 5 patients;Transplant Immunology;2023-02
5. Improving Cell Reinfusion to Enhance the Efficacy of Chimeric Antigen Receptor T-Cell Therapy and Alleviate Complications;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3